Insulin Injection Aids Market Size, Share & Trends Analysis Report By Product (Insulin Vial Aids, Syringe Aids, Injectors, Aids for Kids), By End-use, By Region, And Segment Forecasts, 2024 - 2030
Insulin Injection Aids Market Growth & Trends
The global insulin injection aids market size is anticipated to reach USD 378.7 million by 2030, growing at a CAGR of from 2024 to 2030, according to a new report by Grand View Research, Inc. A major factor propelling the market for insulin injection aids is the rising prevalence of diabetes. Furthermore, increasing preference for advanced insulin administration methods over conventional vials and syringes, such as insulin pumps, injectors, and pens is fueling the market.
Growing prevalence of diabetes is leading to the higher demand for the insulin injection aids. For instance, according to the report published by IDF Diabetes Atlas, in 2022, 537 Million adults had diabetes - 1 in 10. This number is expected to rise to 634 Million by 2030 and 783 Million by 2045. The availability of insulin injection aids makes it easier to administer insulin precisely and conveniently, which helps with better diabetes care.
Additionally, technological advancements are another factor driving the growth of the market. Technological advancements have enabled the creation of more advanced and user-friendly insulin delivery systems. To enhance the entire experience for individuals with diabetes, technological advancements have had a considerable impact on the development of insulin injection aids. For instance, syringe magnifiers are developed for the people with poor vision, the markings and number on the syringe are enlarged with this device to help the patients read the dosage requirements on the syringe. Moreover, I-Port Injection Port developed by Medtronic plc is a port that should be worn for up to three days on the skin to avoid skin puncture at every insulin dose. Additionally, syringe filling devices, injectors such as pen or auto injectors are designed to help people for better diabetes management.
Insulin Injection Aids Market Report Highlights
- Based on products, syringe aids segment dominated the market in 2023, with a share of 38.77% owing to the rising prevalence of diabetes
- Based on end-use, home care settings segment dominated the market with a share of 45.36% in 2023. The convenience, individualized treatments, and potential cost savings contributed to its largest market share.
- North America led the market with the maximum revenue share in 2023, owing to the increasing number of patients suffering from diabetes.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. End-use
- 1.2.3. Regional scope
- 1.2.4. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. End Use outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Insulin Injection Aids Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising prevalence of diabetes globally
- 3.2.1.2. Growing geriatric population
- 3.2.1.3. Growing awareness and education about diabetes management
- 3.2.1.4. Expansion of healthcare infrastructure
- 3.2.2. Market restraint analysis
- 3.2.2.1. Lack of awareness in emerging markets
- 3.2.2.2. Poor reimbursement scenarios
- 3.3. Insulin Injection Aids Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- Chapter 4. Insulin Injection Aids Market: Product Estimates & Trend Analysis
- 4.1. Product Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global Insulin Injection Aids Market by Product Outlook
- 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5. Insulin Vial Aids Market
- 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.6. Syringe Aids Market
- 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.7. Injectors Market
- 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.8. Aids for Kids Market
- 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.9. Others Market
- 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Insulin Injection Aids Market: End-use Estimates & Trend Analysis
- 5.1. End-use Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global Insulin Injection Aids Market by End-use Outlook
- 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5. Hospitals
- 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.6. Specialty Clinics
- 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.7. Home Care Settings
- 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.8. Others
- 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Insulin Injection Aids Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2023 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Global Regional Market Snapshot
- 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 6.5. North America
- 6.5.1. U.S.
- 6.5.1.1. Key country dynamics
- 6.5.1.2. Regulatory framework/ reimbursement structure
- 6.5.1.3. Competitive scenario
- 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Canada
- 6.5.2.1. Key country dynamics
- 6.5.2.2. Regulatory framework/ reimbursement structure
- 6.5.2.3. Competitive scenario
- 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. Mexico
- 6.5.3.1. Key country dynamics
- 6.5.3.2. Regulatory framework/ reimbursement structure
- 6.5.3.3. Competitive scenario
- 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6. Europe
- 6.6.1. UK
- 6.6.1.1. Key country dynamics
- 6.6.1.2. Regulatory framework/ reimbursement structure
- 6.6.1.3. Competitive scenario
- 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.2. Germany
- 6.6.2.1. Key country dynamics
- 6.6.2.2. Regulatory framework/ reimbursement structure
- 6.6.2.3. Competitive scenario
- 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.3. France
- 6.6.3.1. Key country dynamics
- 6.6.3.2. Regulatory framework/ reimbursement structure
- 6.6.3.3. Competitive scenario
- 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.4. Italy
- 6.6.4.1. Key country dynamics
- 6.6.4.2. Regulatory framework/ reimbursement structure
- 6.6.4.3. Competitive scenario
- 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.5. Spain
- 6.6.5.1. Key country dynamics
- 6.6.5.2. Regulatory framework/ reimbursement structure
- 6.6.5.3. Competitive scenario
- 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.6. Norway
- 6.6.6.1. Key country dynamics
- 6.6.6.2. Regulatory framework/ reimbursement structure
- 6.6.6.3. Competitive scenario
- 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.7. Sweden
- 6.6.7.1. Key country dynamics
- 6.6.7.2. Regulatory framework/ reimbursement structure
- 6.6.7.3. Competitive scenario
- 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.6.8. Denmark
- 6.6.8.1. Key country dynamics
- 6.6.8.2. Regulatory framework/ reimbursement structure
- 6.6.8.3. Competitive scenario
- 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Key country dynamics
- 6.7.1.2. Regulatory framework/ reimbursement structure
- 6.7.1.3. Competitive scenario
- 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.2. China
- 6.7.2.1. Key country dynamics
- 6.7.2.2. Regulatory framework/ reimbursement structure
- 6.7.2.3. Competitive scenario
- 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.3. India
- 6.7.3.1. Key country dynamics
- 6.7.3.2. Regulatory framework/ reimbursement structure
- 6.7.3.3. Competitive scenario
- 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.4. Australia
- 6.7.4.1. Key country dynamics
- 6.7.4.2. Regulatory framework/ reimbursement structure
- 6.7.4.3. Competitive scenario
- 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.5. South Korea
- 6.7.5.1. Key country dynamics
- 6.7.5.2. Regulatory framework/ reimbursement structure
- 6.7.5.3. Competitive scenario
- 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 6.7.6. Thailand
- 6.7.6.1. Key country dynamics
- 6.7.6.2. Regulatory framework/ reimbursement structure
- 6.7.6.3. Competitive scenario
- 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Key country dynamics
- 6.8.1.2. Regulatory framework/ reimbursement structure
- 6.8.1.3. Competitive scenario
- 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 6.8.2. Argentina
- 6.8.2.1. Key country dynamics
- 6.8.2.2. Regulatory framework/ reimbursement structure
- 6.8.2.3. Competitive scenario
- 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Key country dynamics
- 6.9.1.2. Regulatory framework/ reimbursement structure
- 6.9.1.3. Competitive scenario
- 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.2. Saudi Arabia
- 6.9.2.1. Key country dynamics
- 6.9.2.2. Regulatory framework/ reimbursement structure
- 6.9.2.3. Competitive scenario
- 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.3. UAE
- 6.9.3.1. Key country dynamics
- 6.9.3.2. Regulatory framework/ reimbursement structure
- 6.9.3.3. Competitive scenario
- 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 6.9.4. Kuwait
- 6.9.4.1. Key country dynamics
- 6.9.4.2. Regulatory framework/ reimbursement structure
- 6.9.4.3. Competitive scenario
- 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company market share analysis, 2023
- 7.4. Company Profiles
- 7.4.1. Medtronic Plc
- 7.4.1.1. Company overview
- 7.4.1.2. Financial performance
- 7.4.1.3. Product benchmarking
- 7.4.1.4. Strategic initiatives
- 7.4.2. Convatec Inc.
- 7.4.2.1. Company overview
- 7.4.2.2. Financial performance
- 7.4.2.3. Product benchmarking
- 7.4.2.4. Strategic initiatives
- 7.4.3. Becton, Dickinson and Co.
- 7.4.3.1. Company overview
- 7.4.3.2. Financial performance
- 7.4.3.3. Product benchmarking
- 7.4.3.4. Strategic initiatives
- 7.4.4. AmbiMedInc.
- 7.4.4.1. Company overview
- 7.4.4.2. Financial performance
- 7.4.4.3. Product benchmarking
- 7.4.4.4. Strategic initiatives
- 7.4.5. Medicool
- 7.4.5.1. Company overview
- 7.4.5.2. Financial performance
- 7.4.5.3. Product benchmarking
- 7.4.5.4. Strategic initiatives
- 7.4.6. TickleTec Ltd
- 7.4.6.1. Company overview
- 7.4.6.2. Financial performance
- 7.4.6.3. Product benchmarking
- 7.4.6.4. Strategic initiatives
- 7.4.7. Pain Care Labs
- 7.4.7.1. Company overview
- 7.4.7.2. Financial performance
- 7.4.7.3. Product benchmarking
- 7.4.7.4. Strategic initiatives
- 7.4.8. Apothecary Products
- 7.4.8.1. Company overview
- 7.4.8.2. Financial performance
- 7.4.8.3. Product benchmarking
- 7.4.8.4. Strategic initiatives
- 7.4.9. BIONIX LLC
- 7.4.9.1. Company overview
- 7.4.9.2. Financial performance
- 7.4.9.3. Product benchmarking
- 7.4.9.4. Strategic initiatives
- 7.4.10. Prodigy Diabetes Care, LLC
- 7.4.10.1. Company overview
- 7.4.10.2. Financial performance
- 7.4.10.3. Product benchmarking
- 7.4.10.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook